Company profile
BICARA THERAPEUTICS INC.
NASDAQ:BCAXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FICERAFUSP ALFA | phase2_3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07807163 | phase2 | recruiting | 2026-09-01 | 2028-03-01 | Bicara Therapeutics | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC |
| NCT06788990 | phase2_3 | recruiting | 2025-01-28 | 2028-04-01 | Bicara Therapeutics | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
| NCT04429542 | phase1 | recruiting | 2020-06-01 | 2027-10-31 | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
FDA applications (0)
No records yet.